-
Views
-
Cite
Cite
Jose Luis Zamorano, Patrizio Lancellotti, Daniel Rodriguez Muñoz, Victor Aboyans, Riccardo Asteggiano, Maurizio Galderisi, Gilbert Habib, Daniel J Lenihan, Gregory Y H Lip, Alexander R Lyon, Teresa Lopez Fernandez, Dania Mohty, Massimo F Piepoli, Juan Tamargo, Adam Torbicki, Thomas M Suter, ESC Scientific Document Group , 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), European Heart Journal, Volume 37, Issue 36, 21 September 2016, Pages 2768–2801, https://doi.org/10.1093/eurheartj/ehw211
- Share Icon Share
Extract
Table of Contents
...
Abbreviations and acronyms
...
Preamble
Guidelines and position papers written under the auspices of the ESC Committee for Practice Guidelines (CPG) summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. CPG Guidelines and position papers should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to CPG policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist.